New hope for Tough-to-Treat colorectal cancer: drug combo shows promise in Late-Stage trial
NCT ID NCT07261709
First seen Jan 02, 2026 · Last updated May 08, 2026 · Updated 18 times
Summary
This study compares two drug combinations for people with advanced colorectal cancer that has stopped responding to standard therapies. About 236 adults will receive either a new combination (trifluridine/tipiracil plus fruquintinib) or the current standard (trifluridine/tipiracil plus bevacizumab). The goal is to see if the new combo works as well or better at controlling the cancer and improving survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the first affiliated hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080
Guangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.